Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132808
Status:
COMPLETED
Last Update Posted:
2016-09-12
First Post:
2005-08-18
Brief Title:
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia 45 Years of Age and Older
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 2-year Randomized Multicenter Double-blind Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Osteoporosis prevention is important in patients with osteopenia low bone density This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None